Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049276 · ClinicalTrials.gov registry record · NA
The Multicentre Selective Lymphadenectomy Trial - 3
A NA study of Cutaneous Melanoma, Stage III, sponsored by Melanoma Institute Australia.
- Recruiting
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 6
- Study locations
NCT07049276: Recruiting NA study of Cutaneous Melanoma, Stage III, sponsored by Melanoma Institute Australia.
NCT07049276 is a NA study of Cutaneous Melanoma, Stage III that is actively recruiting participants, run by Melanoma Institute Australia. The registered enrollment target is 1,500 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07049276, a NA study of Cutaneous Melanoma, Stage III, is actively recruiting participants, sponsored by Melanoma Institute Australia.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less wound problems \& lymphoedema), an improved quality of life, at a lower healthcare utilisation.
Primary Outcome
The proportion of patients with a major pathological response (MPR) alive and disease-free from the time of surgery to the end of 2 years follow up
Conditions Studied
Interventions
- PROCEDURE Index lymph node resection
- PROCEDURE Therapeutic lymph node dissection
Study Locations (6)
Other
- San Maria della Misericordia Hospital - Perugia
- The Royal Marsden - London
California
- Cedars-Sinai Medical Centre - Los Angeles
New South Wales
- Melanoma Institute Australia - Wollstonecraft
Ontario
- Sunnybrook Health Sciences Centre - Toronto
Auklnad
- North Shore Hospital - Takapuna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2040-08 |
| Phase | NA |
What NCT07049276 shows while recruiting
NCT07049276 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 1 condition, with Cutaneous Melanoma, Stage III appearing as the primary indexed condition, and to 2 interventions - of which Index lymph node resection is the first listed.
NCT07049276 lists 6 locations in 5 states (Other, California, New South Wales).
Frequently Asked Questions
What is clinical trial NCT07049276 about?
NCT07049276 is a clinical study titled "The Multicentre Selective Lymphadenectomy Trial - 3". The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either s...
What is the current status of trial NCT07049276?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2025-10-01. Estimated completion is 2040-08.
What conditions does trial NCT07049276 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Stage III.
What interventions are being tested in trial NCT07049276?
The interventions under investigation include: Index lymph node resection (PROCEDURE), Therapeutic lymph node dissection (PROCEDURE).
Who is sponsoring clinical trial NCT07049276?
This trial is sponsored by Melanoma Institute Australia, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049276 being conducted?
This trial has 6 study locations across California, New South Wales, Ontario, Auklnad. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma, Stage III
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07049276's enrollment target sits among peer trials
1,500 65th of 2000 higher than 1,933 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI